These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. Konduru K; Bradfute SB; Jacques J; Manangeeswaran M; Nakamura S; Morshed S; Wood SC; Bavari S; Kaplan GG Vaccine; 2011 Apr; 29(16):2968-77. PubMed ID: 21329775 [TBL] [Abstract][Full Text] [Related]
29. Open-label phase I clinical trial of Ad5-EBOV in Africans in China. Wu L; Zhang Z; Gao H; Li Y; Hou L; Yao H; Wu S; Liu J; Wang L; Zhai Y; Ou H; Lin M; Wu X; Liu J; Lang G; Xin Q; Wu G; Luo L; Liu P; Shentu J; Wu N; Sheng J; Qiu Y; Chen W; Li L Hum Vaccin Immunother; 2017 Sep; 13(9):2078-2085. PubMed ID: 28708962 [TBL] [Abstract][Full Text] [Related]
32. Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease. Wang H; Wong G; Zhu W; He S; Zhao Y; Yan F; Rahim MN; Bi Y; Zhang Z; Cheng K; Jin H; Cao Z; Zheng X; Gai W; Bai J; Chen W; Zou Y; Gao Y; Gao GF; Yang S; Xia X; Qiu X J Virol; 2019 Mar; 93(5):. PubMed ID: 30541860 [TBL] [Abstract][Full Text] [Related]
33. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus. Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675 [TBL] [Abstract][Full Text] [Related]
34. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Bukreyev A; Marzi A; Feldmann F; Zhang L; Yang L; Ward JM; Dorward DW; Pickles RJ; Murphy BR; Feldmann H; Collins PL Virology; 2009 Jan; 383(2):348-61. PubMed ID: 19010509 [TBL] [Abstract][Full Text] [Related]
36. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals. Wong G; Richardson JS; Cutts T; Qiu X; Kobinger GP Antiviral Res; 2015 Apr; 116():17-9. PubMed ID: 25596432 [TBL] [Abstract][Full Text] [Related]
37. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. Luczkowiak J; Arribas JR; Gómez S; Jiménez-Yuste V; de la Calle F; Viejo A; Delgado R Virus Res; 2016 Feb; 213():224-229. PubMed ID: 26739425 [TBL] [Abstract][Full Text] [Related]
38. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083 [TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. Dolzhikova IV; Zubkova OV; Tukhvatulin AI; Dzharullaeva AS; Tukhvatulina NM; Shcheblyakov DV; Shmarov MM; Tokarskaya EA; Simakova YV; Egorova DA; Scherbinin DN; Tutykhina IL; Lysenko AA; Kostarnoy AV; Gancheva PG; Ozharovskaya TA; Belugin BV; Kolobukhina LV; Pantyukhov VB; Syromyatnikova SI; Shatokhina IV; Sizikova TV; Rumyantseva IG; Andrus AF; Boyarskaya NV; Voytyuk AN; Babira VF; Volchikhina SV; Kutaev DA; Bel'skih AN; Zhdanov KV; Zakharenko SM; Borisevich SV; Logunov DY; Naroditsky BS; Gintsburg AL Hum Vaccin Immunother; 2017 Mar; 13(3):613-620. PubMed ID: 28152326 [TBL] [Abstract][Full Text] [Related]